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Introduction: The aim of this study was to investigate the effects of thyroid hormones tri-iodothyronine (T3),
thyroxine (T4), and parathyroid hormone (PTH) from the parathyroid glands, known to regulate the developing limb
and growth plate, on articular cartilage tissue regeneration using a scaffold-free in vitro model.
Methods: In Phase 1, T3, T4, or PTH was applied during weeks 1 or 3 of a 4-week neocartilage culture. Phase 2
employed T3 during week 1, followed by PTH during week 2, 3, or weeks 2 to 4, to further enhance tissue properties.
Resultant neotissues were evaluated biochemically, mechanically, and histologically.
Results: In Phase 1, T3 and T4 treatment during week 1 resulted in significantly enhanced collagen production;
1.4- and 1.3-times untreated neocartilage. Compressive and tensile properties were also significantly increased, as
compared to untreated and PTH groups. PTH treatment did not result in notable tissue changes. As T3 induces
hypertrophy, in Phase 2, PTH (known to suppress hypertrophy) was applied sequentially after T3. Excitingly,
sequential treatment with T3 and PTH reduced expression of hypertrophic marker collagen X, while yielding
neocartilage with significantly enhanced functional properties. Specifically, in comparison to no hormone
application, these hormones increased compressive and tensile moduli 4.0-fold and 3.1-fold, respectively.
Conclusions: This study demonstrated that T3, together with PTH, when applied in a scaffold-free model of
cartilage formation, significantly enhanced functional properties. The novel use of these thyroid hormones
generates mechanically robust neocartilage via the use of a scaffold-free tissue engineering model.Introduction
Surgical treatment options for patients with articular car-
tilage damage range from pain-alleviating microfracture
techniques to end-stage total knee arthroplasty, with in-
creasing numbers of developing therapies focused on
avoiding joint replacement [1]. Nonsurgical options typic-
ally involve injection of pain-relieving, anti-inflammatory
treatments that reduce inflammation in the joint space, or
chondroprotective agents that serve to enhance lubrica-
tion and prevent further matrix degradation [2,3]. In gen-
eral, therapies are limited to mediating the osteoarthritic
environment and do not serve to facilitate active cartilage
repair. Cartilage tissue engineering has emerged as a po-
tential method to treat focal cartilage defects, thereby
delaying the need for total joint arthroplasty.* Correspondence: athanasiou@ucdavis.edu
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stated.A scaffold-free tissue engineering approach, based on
a self-assembling process, recapitulates cartilage develop-
ment [4,5] and is amenable to the application of chemical
and mechanical stimuli to drive cartilage matrix synthesis
and maturation [6,7]. Application of exogenous agents
can produce neocartilage with mechanical properties
approaching those of native cartilage tissue; for example,
stimulated self-assembled neocartilage can possess a com-
pressive stiffness over 200 kPa [7], in range of native
articular cartilage values [8]. More recently, cartilage de-
velopmental biology has driven the identification of new
stimuli suitable for use in the self-assembling process, to-
ward better enhancing the mechanical and biochemical
properties of engineered neocartilage.
During skeletal development, the thyroid hormones tri-
iodothyronine (T3), thyroxine (T4), and parathyroid hor-
mone (PTH) from the parathyroid glands function in a
highly coordinated fashion to regulate the phenotype of
growth plate chondrocytes, as well as the progression of
cartilage growth during endochondral ossification [9-11].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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maintaining the proliferative pool of chondrocytes, while
T3 promotes the transition from proliferative to hyper-
trophic chondrocytes. T4 is converted to T3 by removal of
an iodine moiety by membrane-bound de-iodinase cell re-
ceptors [12]. In growth plate chondrocytes, PTH signaling
targets upregulation of Sox9, a major regulatory gene of
articular cartilage [13]. On the other hand, T3 signals
through the canonical Wnt pathway, targeting the upregu-
lation of Runx2 [14]. While the roles of PTH, T3, and T4
are well established in skeletal development - specifically,
in the growth plate - the effects of these thyroid hormones
on chondrocytes of articular cartilage, and, in turn, on
their ability to repair or regenerate articular cartilage, is
not well understood.
Recently, the intra-articular injection of PTH in osteo-
arthritic animal models has been explored as a potential
therapeutic to promote cartilage matrix production [15-17].
These studies found that PTH (1-34) (that is, PTH frag-
ment 1-34), particularly when administered intermittently,
could reduce collagen type X deposition, while recovering
glycosaminoglycan (GAG) and collagen type II levels, as
evaluated via tissue staining. In addition, PTH (1-34) was
shown to improve the gross morphological surface topog-
raphy and histological appearance of repair cartilage [18].
By demonstrating reduction in hypertrophic markers and
promoting an articular cartilage phenotype, these studies
highlight the ability of articular chondrocytes to respond to
PTH and suggest its use in repairing or regenerating ar-
ticular cartilage. Conclusions from these studies, however,
are primarily derived from gross morphological and
histological evaluation. Therefore, while the potential for
thyroid hormones to facilitate cartilage repair is apparent,
studies that quantify the tissue-level changes beyond quali-
tative methods by evaluating the matrix components (that
is, collagen and GAG) and functional mechanical proper-
ties of repair cartilage are needed.
Limited studies use T3 and T4 to specifically improve
the functional properties of neocartilage engineered from
articular chondrocytes, as existing studies largely focus on
understanding hormone effects at the cellular level. For
instance, T3, when applied to alginate-embedded chon-
drocytes, enhanced the hydroxyproline content per cell
[19]. In the presence of bone morphogenetic protein 2
(BMP-2) and insulin, T3 significantly increased collagen
type II mRNA and reduced BMP-2/insulin-induced colla-
gen type X expression [20]. These studies demonstrate the
beneficial effects of T3 in eliciting increased collagen pro-
duction in articular chondrocytes in three-dimensional
culture. However, the effect of T3 and T4 hormones on
increasing the functional properties of engineered neocar-
tilage is understudied.
Recent advances have employed PTH as a potential
therapeutic for articular cartilage repair or regenerationand have described the interactions of PTH and T3 in
the development of the growth plate; however, the use of
these hormones in cartilage tissue engineering is limited
by our understanding of their effects specifically on articu-
lar chondrocytes. The objective of this study was, thus, to
evaluate thyroid hormones PTH, T3, and T4 in neocarti-
lage engineering to ascertain their effects on generating
mechanically functional tissues. In Phase 1, each hormone
was applied at an early (week 1) or late (week 3) point of
neocartilage formation with a total culture time of 4 weeks.
T3 use during week 1 most significantly enhanced neocar-
tilage biochemical and mechanical properties and was car-
ried forward to Phase 2. Phase 2 of this study applied PTH
sequentially after T3 to modulate the hypertrophic re-
sponse elicited by T3. This study was motivated by the
hypothesis that application of thyroid hormones to articu-
lar chondrocytes in an in vitro model of scaffold-free cartil-
age regeneration would induce matrix maturation and
enhance matrix properties; in particular, sequential applica-
tion of T3 and PTH was hypothesized to enhance neocarti-
lage properties without hypertrophic marker expression.
Materials and methods
Chondrocyte isolation
Eight juvenile bovine joints were purchased from an abat-
toir for research purposes; no permission was needed to
use the joints (Research 87, Boston, MA, USA). Within 48
hrs, articular chondrocytes were harvested from the distal
femurs. Tissue was digested in 0.2% collagenase type II
(Worthington Biochemical Corp., Lakewood, NJ, USA) for
18 hrs. Cells were washed in Dulbecco’s modified Eagle’s
medium (DMEM) containing 1% penicillin-streptomycin-
fungizone (PSF; Lonza BioWhittaker, Walkersville, MD,
USA) before freezing in 20% fetal bovine serum and 10%
dimethyl sulfoxide medium. Cells were stored at −80°C
until use. Cells used in Phases 1 and 2 of this study were
not sourced from the same eight bovine joints, contribut-
ing to biological variability in the results; however, results
of this study are within range of prior work employing the
self-assembling process.
Scaffold-free in vitro neocartilage formation
To generate scaffold-free constructs, 5.32 M cells in Phase
1 and 4.57 M cells in Phase 2 were seeded into 5 mm-
diameter nonadherent agarose (2% wt/vol phosphate-
buffered saline (PBS)) wells, as previously described [21].
Agarose wells (1 mL) were presaturated with chondro-
genic medium, and constructs were supplied with an add-
itional 0.5 mL chondrogenic medium daily. Chondrogenic
medium consists of: DMEM with GlutaMAX (Gibco,
Grand Island, NY, USA); 0.1 mM nonessential amino
acids (Gibco); 1% insulin, human transferrin, and selenous
acid (ITS+; BD Biosciences, San Jose, CA, USA); 1% PSF
(Lonza BioWhittaker); 100 nM dexamethasone (Sigma-
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phosphate (Sigma-Aldrich); 100 μg/mL sodium pyruvate
(Sigma-Aldrich) and 40 μg/mL L-proline (Sigma-Aldrich).
When constructs grew to the edge of the agarose well,
they were transferred to 48-well plates containing 1 mL
chondrogenic medium to allow for continued growth
until 28 days of culture. The full volume of medium was
exchanged daily.
Hormone application
Phase 1 of this study applied 100 ng/mL PTH 1-34
(Sigma-Aldrich, P3671), T3 (Sigma-Aldrich, T6397), or
T4 (Sigma-Aldrich, T2376) during week 1 (that is, daily
for days 1 to 7) or week 3 (that is, daily for days 15 to
21) of a 4-week culture period. A concentration of 100 ng/
mL was chosen to maximize the potential of a cellular re-
sponse [11,22,23]. Phase 2 evaluated the use of 25 ng/mL
PTH during week 2 (that is, daily for days 8 to 14), week 3
(that is, daily for days 15 to 21), or weeks 2 to 4 (that is,
daily for days 8 to 28) sequentially after 0 or 100 ng/mL
T3 application during week 1. A dosing study using PTH
(0, 5, 10, 25, 50, and 100 ng/mL) revealed no differences
in any measured parameters, with the exception of 25 ng/
mL PTH being the highest concentration to result in the
highest cellular content (Additional file 1). A concentra-
tion of 25 ng/mL PTH was thus selected for use in Phase
2. All controls received no hormone treatment.
Gross morphological analysis
After 4 weeks of culture, samples were imaged to obtain
dimensions for construct diameter and thickness using
ImageJ software (National Institutes of Health, Bethesda,
MD, USA). Wet weights (mg) were recorded before sam-
ples were portioned for mechanical, biochemical, and histo-
logical analyses.
Mechanical analysis
A 3 mm-diameter biopsy punch was used to obtain a
compressive sample from the construct (Additional file 2),
which was then subjected to creep indentation testing. A
0.8 mm-diameter flat, porous indenter tip was applied to
samples using a 0.7 g or 2 g mass to achieve strains under
12%. The sample’s measured aggregate modulus (HA), per-
meability (k), and Poisson’s ratio (ν) were obtained using a
semi-analytical, semi-numeric, linear biphasic model [24].
Also using a 3 mm-diameter biopsy punch, dog bone-
shaped specimens with a 1.45 mm gauge length were
portioned from constructs (Additional file 2). Dog bone-
shaped specimens used in this study adhered to ASTM
standard testing guidelines [25] to ensure failure at the
mid-point of the sample. After gluing dog bones to paper
tabs outside of the gauge length, tabs were gripped in a
uniaxial materials testing system (TestResources Inc.,
Shakopee, MN, USA). Samples were pulled at 1% of thegauge length per second until failure. Sample cross-
sectional area was measured in ImageJ and used to gener-
ate a stress-strain curve. A least-squares fit of the linear
region of the curve yielded the tensile stiffness (Young’s
modulus, EY) and the maximum stress reached yielded
the ultimate tensile strength (UTS).
Biochemical analysis
Samples portioned for biochemical analysis were weighed
wet before freezing and lyophilizing. Samples were weighed
dry before digestion in 125 μg/mL papain (Sigma-Aldrich)
for 18 hrs at 65°C. A PicoGreen assay (Invitrogen,
Carlsbad, CA, USA) was used to assess total DNA con-
tent in constructs and converted to total cell number
assuming 7.7 pg DNA/cell. Total GAG content was de-
termined using a Blyscan Glycosaminoglycan Assay
(Biocolor, Carrickfergus, UK). Total collagen content was
evaluated via a modified chloramine-T hydroxyproline
assay [26]. A standard curve reflecting collagen amount
was generated using a Sircol collagen standard (Biocolor).
Both GAG and collagen contents were normalized to con-
struct wet weight and dry weight.
Histological and immunohistochemical analysis
Samples portioned for histological analysis were cryoem-
bedded, sectioned at 14 μm, and fixed in 10% formalin.
To visualize collagen and GAG distribution, samples were
stained with picrosirius red and Safranin-O/Fast Green,
respectively. Alizarin Red staining was used to assess
mineralization. For Phase 2, Safranin-O/Fast Green images
were used to quantify cell diameter using ImageJ software;
specifically, 6 cells from each of 8 images were assessed
for a total of 48 measurements per group. While tissue
volumetric changes may occur during embedding, all sam-
ples were handled identically. As a result, calculated cell
diameters apply only for cryoembedded, formalin-fixed
samples. Immunohistochemistry was performed for col-
lagen type II and X. Briefly, slides were fixed in acetone
for 20 min at 4°C. Endogenous peroxidases were
quenched with 3% hydrogen peroxide in methanol be-
fore blocking with 1% bovine serum albumin. The pri-
mary antibody (rabbit anti-collagen type II (Fitzgerald
Industries International, Acton, MA, USA) and mouse
anti-collagen type X (Abcam, Cambridge, UK)) was applied
for 1 hr, followed by horseradish peroxidase-conjugated
secondary antibody for 30 min (Vector Laboratories,
Burlingame, CA, USA). Visualization of antibody local-
ization was performed using 3,3′-diaminobenzidine
(DAB) reagent (Vector Laboratories).
Statistical analysis
One-way and two-way analysis of variance (ANOVA)
designs were employed in Phase 1 and 2, respectively,
followed by Tukey’s post hoc test (P <0.05). JMP 9.0.1
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statistical analyses. An n = 4-6 was used for Phase 1, and
n = 6-8 was used for Phase 2. Groups not connected by
the same symbol are statistically significant, and data are
represented as mean ± standard deviation.Results
Gross morphology
Neocartilage gross morphology is shown in Figures 1A
and 2A. All constructs appeared hyaline-like; T3-treated
constructs in Phase 2 exhibit curvature. The gross mor-
phological properties and cellular content are shown in
Table 1. Notably, in Phase 1, T3 and T4 application at week
1 significantly reduced neocartilage wet weight, water con-
tent, diameter, and thickness, as compared to untreated
constructs. PTH treatment at week 1 or 3 did not result in
significant changes. In Phase 2, T3 again yielded neocar-
tilage with significantly reduced gross morphological
parameters. Phase 1 and 2 control morphologies differ
as a result of a reduced seeding density (5.32 M cells in
Phase 1 and 4.57 M cells in Phase 2) and biological vari-
ability in the cell source.Figure 1 Phase 1 construct morphology and histological analysis. All
yielded smaller, thinner constructs, as compared to PTH and untreated con
GAG, glycosaminoglycan; PTH, parathyroid hormone; T3, tri-iodothyronine;Histological assessment
Histological results of this study are illustrated in Figures 1B
and 2B. Constructs from both phases demonstrated robust
production of GAG, as indicated by Safranin-O/Fast Green
staining, as well as collagen, as indicated by picrosirius red
staining. Differences in staining intensity among hormone
treatments were not apparent. Alizarin Red staining was
negative for all groups (data not shown). In Phase 2, cell
diameters, as measured from Safranin-O/Fast Green im-
ages, are shown in Figure 2C. T3 resulted in a statisti-
cally significant increase in cell diameter, as compared
to non-T3 treated groups. Specifically, diameters were
increased from 12.0 ± 0.9 μm to 14.8 ± 1.0 μm with T3
treatment. Sequential treatment with PTH did not have
an effect on cell diameter.
Mechanical properties
Construct functional properties, as assessed by compres-
sive and tensile evaluation, are shown in Figure 3. In
Phase 1 of this study, T3 and T4 application during week
1 led to significant enhancement of compressive and
tensile properties. Specifically, T3 and T4 treatment dur-
ing week 1 increased the aggregate modulus, a measureconstructs appeared smooth and hyaline-like. T3 and T4 treatments
trols (A). Collagen and GAG staining was uniform in all constructs (B).
T4, thyroxine.
Figure 2 Phase 2 construct morphology, histological analysis, and cell diameter quantification. Phase 2 constructs exhibited no
abnormalities and were hyaline-like in appearance. Notably, T3 treatment produced neocartilage with pronounced curvature, suggestive of
tissue prestress (A). Picrosirius red and Safranin-O dyes demonstrated robust deposition of collagen and GAG, respectively, in all constructs (B).
T3-treated groups possessed more GAG staining than non-T3 treated groups. T3 elicited an increase in cell diameter (C), as measured for
cryoembedded, formalin-fixed samples. Groups not connected by the same letter are statistically significant. Data are represented as mean ±
standard deviation. GAG, glycosaminoglycan; T3, tri-iodothyronine.
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respectively, as compared to control values of 138 ± 67
kPa. T3 treatment at week 1 also had the most significant
effect on tensile properties - resulting in a Young’s
modulus and UTS of 1.90 ± 0.42 MPa and 0.59 ± 0.16
MPa, respectively, as compared to control values of
0.97 ± 0.32 MPa and 0.24 ± 0.05 MPa for Young’s modu-
lus and UTS, respectively.In Phase 2 of this work, T3 treatment again contributed
to significant enhancement of compressive and tensile
properties. T3-treated neocartilage exhibited an aggregate
modulus of 260 ± 12 kPa as compared to non-T3 treated
constructs of 65 ± 3 kPa. The Young’s modulus was in-
creased from 0.51 ± 0.05 MPa for constructs receiving no
T3, to 1.60 ± 0.19 MPa for constructs treated with T3.
PTH treatments, applied alone or sequentially after T3 in
Table 1 Construct morphology and cellular content
Group Wet weight (mg) Water content (%) Diameter (mm) Thickness (mm) Cells (×10^6)
Phase 1
Control 32.9 ± 1.0AB 89.7 ± 2.3A 6.18 ± 0.14A 0.81 ± 0.15A 3.72 ± 0.45AB
Week 1 Treatment PTH 33.9 ± 1.0A 89.4 ± 0.6A 6.09 ± 0.09A 0.77 ± 0.05A 3.57 ± 0.20AB
T3 17.1 ± 0.5C 85.0 ± 0.8B 5.66 ± 0.05B 0.54 ± 0.07B 3.10 ± 0.11BC
T4 17.8 ± 0.7C 85.3 ± 1.4B 5.80 ± 0.09B 0.53 ± 0.02B 2.87 ± 0.24C
Week 3 Treatment PTH 31.5 ± 1.4B 88.3 ± 0.5A 6.28 ± 0.12A 0.69 ± 0.05A 3.54 ± 0.30AB
T3 32.8 ± 1.0AB 87.8 ± 0.6A 6.24 ± 0.05A 0.72 ± 0.05A 3.60 ± 0.26AB
T4 33.0 ± 1.3AB 88.3 ± 0.8A 6.18 ± 0.09A 0.74 ± 0.03A 3.71 ± 0.30A
Phase 2
No T3 Treatment Control 15.4 ± 0.6a 89.5 ± 0.5a 5.65 ± 0.13ab 0.56 ± 0.05ab 2.85 ± 0.27a
PTH Week 2 16.6 ± 1.5a 89.6 ± 0.6a 5.71 ± 0.10ab 0.61 ± 0.04a 3.00 ± 0.21a
PTH Week 3 16.1 ± 0.5a 89.4 ± 0.3a 5.71 ± 0.08ab 0.60 ± 0.03a 3.01 ± 0.20a
PTH Week 2-4 16.2 ± 0.5a 89.1 ± 0.4a 5.80 ± 0.09a 0.85 ± 0.03ab 2.74 ± 0.47a
Week 1 T3 Treatment No PTH 13.4 ± 0.9b 84.9 ± 1.0b 5.67 ± 0.12ab 0.55 ± 0.08ab 2.71 ± 0.24a
PTH Week 2 14.0 ± 0.7b 84.9 ± 0.6b 5.69 ± 0.23ab 0.57 ± 0.04ab 2.98 ± 0.15a
PTH Week 3 13.1 ± 0.8b 85.6 ± 0.9b 5.53 ± 0.09b 0.59 ± 0.11ab 2.91 ± 0.19a
PTH Week 2-4 13.3 ± 0.6b 84.7 ± 0.6b 5.60 ± 0.16ab 0.49 ± 0.04b 2.72 ± 0.17a
Phase 1 and 2 construct morphology and cellular content. Phase 2 used a lower seeding density (for example, 4.57 versus 5.32 million cells in Phase 1) and
resulted in smaller constructs. Letters represent the statistical results of a one-way and two-way ANOVA for Phase 1 and 2, respectively. Groups not connected by
the same letter are statistically significant. Data are represented as mean ± standard deviation.
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any functional properties of generated neocartilage.
Biochemical content
Neocartilage biochemical composition is shown in Figure 4
(GAG content) and Figure 5 (collagen content). T3 and
T4 application during week 1 resulted in a significant
decrease in GAG content, when normalized to dry
weight, to 0.340 ± 0.016 and 0.377 ± 0.003 mg GAG/mg
dry weight (GAG/DW), respectively, from a control
value of 0.449 ± 0.040 mg/mg. When normalized to tis-
sue wet weight (GAG/WW), however, this reduction of
GAG was not statistically significant. T3 and T4 week 1
treatments led to a significantly higher level of collagen,
increasing collagen per dry weight (COL/DW) of the
neotissue to 0.146 ± 0.007 and 0.139 ± 0.002 mg/mg, re-
spectively, over nontreated controls of 0.103 ± 0.003 mg/
mg. These differences were maintained when collagen
content was normalized to tissue wet weight (COL/WW).
PTH treatment during either week did not result in a sig-
nificant change in GAG or collagen content as compared
to untreated constructs.
T3 application in Phase 2 of this study resulted in a sig-
nificant reduction of GAG content only when normalized
to tissue wet weight. In line with Phase 1 of this work, T3
significantly enhanced collagen content per dry weight to
0.125 ± 0.006 mg/mg, over non-T3 treated constructs of
0.083 ± 0.004 mg/mg. Increased duration of PTH treat-
ment led to reductions in both collagen per DW andWW, with week 3 treatment causing a statistically signifi-
cant reduction in both, as compared to groups that re-
ceived no PTH.
Immunohistochemistry
Figure 6 and Additional file 3 show the results of immu-
nohistochemical assessment of collagen type X and II,
respectively, for Phase 2 of this study. It is well known
that T3 is responsible for promoting the transition of pro-
liferative growth plate chondrocytes into hypertrophic
chondrocytes; however, as the effect of T3 on articular
chondrocytes is yet unclear, immunohistochemistry for
hypertrophic marker collagen type X was conducted. T3
treatment resulted in deposition of collagen type X. When
treated with increasing durations of PTH, however, colla-
gen X staining was decreased. Most notably, sequential
application of PTH for weeks 2 to 4 was most effective at
reducing the staining. PTH treatment alone did not elicit
collagen X deposition. Collagen type II was distributed in
the interterritorial matrix, with no appreciable differences
in collagen type II staining observed among groups.
Discussion
This investigation examined the effects of hormones T3,
T4, and PTH on functional neocartilage formation in an
in vitro model. It was hypothesized that the application
of these thyroid hormones to articular chondrocytes in
an in vitro model of scaffold-free cartilage formation
would induce matrix maturation and enhance matrix
Figure 3 Functional mechanical properties of Phase 1 and 2 neocartilage. In Phase 1, the compressive stiffness (aggregate modulus), tensile
stiffness (Young’s modulus), and ultimate tensile strength were significantly enhanced with T3 and T4 treatments during week 1. PTH treatment
during either week did not have an effect on construct mechanical properties. In Phase 2, T3 elicited significant increases in compressive and
tensile properties. When applied sequentially after T3 in Phase 2, PTH did not alter the T3-induced improvements in mechanical properties.
Groups not connected by the same letter are statistically significant. Data are represented as mean ± standard deviation. PTH, parathyroid
hormone; T3, tri-iodothyronine; T4, thyroxine.
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that scaffold-free neocartilage treated with T3 may exhibit
markers of hypertrophy, but that sequential application of
T3 and PTH would reduce hypertrophic marker expres-
sion. Both hypotheses were shown to be true: (1) applica-
tion of T3 at week 1 elicited a dramatic 4.0- and 3.1-fold
increase in neocartilage compressive and tensile stiffness,
respectively (Phase 2); (2) sequential application of PTH
reduced hypertrophic marker collagen X expression while
maintaining the functional properties elicited by T3. In
addition, T3 treatment resulted in a 2.2- and 1.5-foldincrease in collagen and GAG content, respectively. The
results of this study thus demonstrate that, in our in vitro
model, thyroid hormones have a significant impact on
neocartilage formation, with T3 eliciting the most signifi-
cant increases in functional properties. To our knowledge,
this study is the first to demonstrate that articular chon-
drocytes can indeed respond to T3, T4, and PTH, allowing
them to be employed in an in vitro model of cartilage gen-
eration to produce mechanically robust neocartilage.
Hormone concentrations, gradients, and transients are
tightly coordinated in vivo [27,28]. For example, the
Figure 4 GAG composition of Phase 1 and 2 constructs. Neocartilage GAG composition was normalized to tissue dry weight (GAG/DW) and
wet weight (GAG/WW). No significant change was observed with PTH treatment in Phase 1, while T3 and T4 application during week 1 resulted
in significant changes in GAG/DW. In Phase 2, T3 elicited significantly more GAG/WW production. Notably, when applied sequentially, PTH did
not affect the T3-induced changes in GAG/WW content. Groups not connected by the same letter are statistically significant. Data are represented
as mean ± standard deviation. GAG, glycosaminoglycan; PTH, parathyroid hormone; T3, tri-iodothyronine; T4, thyroxine.
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dral development has been studied by mapping receptor
expression in tissues over time [29]. Recent preclinical
studies utilizing injectable PTH have found that intermit-
tent, but not continuous, application of PTH resulted in
enhanced cartilage regeneration [17], indicating the im-
portance of timing of hormone application. In line with
these results, in Phase 1 of this study, early treatment with
hormones T3 and T4 at week 1 improved properties as
compared to a later treatment at week 3, indicating that
neocartilage is more susceptible to hormone treatment
while the matrix is still in early phases of development.
Earlier treatment may allow for prolonged matrix synthe-
sis, but may also allow for hypertrophy. Phase 2 of this
study similarly demonstrated the importance of hormone
duration. Compared to the other PTH regimens, treatment
during weeks 2 to 4 resulted in the greatest reduction of
collagen type X deposition, suggesting that chondrocytes
require time to respond to hormonal stimuli. Collectively,
this study demonstrates that the timing and duration of
hormone application must be optimized for use as an ap-
propriate stimulus in neocartilage engineering.Extensive exploration into the molecular mechanism
of T3 and PTH signaling has been conducted on growth
plate [30] and limb bud cells [31]. T3 is known to elicit
hypertrophy through Wnt signaling [14] in both growth
plate cells [32] and mesenchymal stem cells (MSCs)
[33-35]. However, the effect of these hormones - par-
ticularly of T3 - on articular chondrocytes and their
subsequent matrix synthesis has not been well studied.
Specifically, investigation into the de-iodinase receptor
profile of osteoarthritic articular chondrocytes has shown
their ability to promote the conversion of T4 to T3 [36].
In addition, differential responses of articular chondro-
cytes from different zones have been demonstrated [37],
but are limited to gene expression and focused on
mineralization, and do not evaluate functional properties.
T3-treatment of alginate-encapsulated articular chondro-
cytes similarly demonstrated changes in gene and protein
content [19]. The present experiment - using a mixed
population of articular chondrocytes - showed that T4
treatment was effective in enhancing neocartilage func-
tional properties in Phase 1. These results thus demon-
strate that juvenile articular chondrocytes are able to
Figure 5 Collagen composition of Phase 1 and 2 constructs. Collagen content was normalized to tissue dry weight (COL/DW) and wet
weight (COL/WW). PTH treatment in Phase 1 did not result in significant changes; however, T3 and T4 application during week 1 or 3 resulted in
significant increases in collagen content. In Phase 2, T3 elicited the same effects. Sequential application of PTH did not alter the increases in
collagen content induced by T3. Groups not connected by the same letter are statistically significant. Data are represented as mean ± standard
deviation. PTH, parathyroid hormone; T3, tri-iodothyronine; T4, thyroxine.
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tent as T3. Also, T3 treatment significantly benefited
functional tissue properties; specifically, T3 increased
neocartilage collagen content 2.2-fold with a paralleled
3.2-fold increase in tensile stiffness, as compared to
non-T3 treated neocartilage. To the best of our know-
ledge, this study is the first to demonstrate the beneficial
functional effects of stimulating articular chondrocytes
with thyroid hormones T3 and PTH to generate mech-
anically robust neocartilage.Figure 6 Immunohistochemical evaluation of Phase 2 neocartilage. T3
duration of sequential PTH application post-T3 treatment reduced collagenAn important finding in this study is that the sequen-
tial application of T3 followed by PTH enhances matrix
formation while mitigating T3′s hypertrophic effects.
Simultaneous application of T3 and PTH does not result
in reduction in collagen type X expression [37], whereas
sequential application of T3 and PTH, in this study, dem-
onstrated a reduction in collagen type X. Mechanistically,
T3 and PTH act on distinct pathways: PTH upregulates
Sox9 and downregulates Runx2; T3 has the opposite ef-
fect by upregulating Runx2 [13]. Together, the balancetreatment caused deposition of collagen X. However, increasing
X staining. PTH, parathyroid hormone; T3, tri-iodothyronine.
Lee et al. Arthritis Research & Therapy  (2015) 17:28 Page 10 of 11of Sox9 and Runx2 regulate hypertrophic marker ex-
pression. Therefore, in this study, T3 application elicited
hypertrophic marker expression, while the subsequent
application of PTH was critical to downregulate hyper-
trophy. Prolonged duration of PTH (that is, weeks 2 to
4) further increased hypertrophic downregulation, as
evident in the reduction of collagen type X in Phase 2.
Excitingly, the functional properties elicited by T3 are
not compromised when PTH is applied, suggesting that
these increased functional properties are not dependent
on the hypertrophic phenotype, but instead represent
robust and persistent hyaline-like matrix maturation.
The novelty of sequential hormone application in this
model of in vitro cartilage generation may lead to the use
of other hormones that, in combination or in sequence,
can be used in cartilage tissue engineering.
Despite the encouraging findings of this work, further
investigation of thyroid hormones and their use in
scaffold-free cartilage engineering is warranted. This
study examined neocartilage after 28 days of culture;
earlier analysis may elucidate the time course of PTH-
induced cellular proliferation or collagen X deposition.
In this study, T3 elicited a hypertrophic cellular morph-
ology (that is, enlarged diameter) that was not mitigated
by PTH; these results may be altered with longer culture
duration. The hormone concentrations and timing of
application for this study were motivated by the existing
literature; however, the use of a scaffold-free system
may justify additional optimization of hormone dosing,
timing, and duration. It is also important to note that
control constructs between Phases 1 and 2 of this study
exhibited differences in wet weight, diameter, and thick-
ness, likely as a result of the reduced seeding density
used in Phase 2. Use of a calcein-based live/dead stain
in future studies may prove informative to assess cell
viability, as the present study employed the trypan blue
assay, which assesses only membrane integrity and not
metabolic activity. Finally, the phenotypic stability and
regenerative potential of neocartilages generated with
hormonal application should be assessed via implant-
ation in an animal model. To build upon this study, fu-
ture work should explore the use of other hormones
and application regimens on the ultimate success of im-
planted neocartilage in vivo.
Conclusions
To the best of our knowledge, this work is the first to
investigate the use of thyroid hormones in scaffold-free
cartilage tissue engineering. In particular, a series of
experiments determined the efficacy of generating ro-
bust neocartilage using thyroid hormones T3 and PTH,
especially when applied sequentially. These hormones
had not previously been examined for their ability to en-
hance articular chondrocyte-based neocartilage functionalproperties. Excitingly, T3 was able to significantly enhance
neocartilage mechanical properties, up to 4-times the
compressive stiffness of untreated controls. Moreover,
T3-induced hypertrophy was mediated by sequential
PTH application. These findings motivate future work
to enhance neocartilage mechanical properties through
the application of other hormones. Neocartilage produced
with sequential hormone stimulation achieved mechanical
properties approaching those of native tissue and may be
applicable for the clinical repair or regeneration of articu-
lar cartilage defects.Additional files
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